Molecular Biomarkers for Localized Prostate Cancer: Current Progress and Future Directions.
1/5 보강
ℹ️ 이 논문은 무료 전문이 아직 없습니다. 코퍼스 전체의 43.6%는 무료 가능 (통계 →) · 🏥 기관 EZproxy로 시도
This article examines the current landscape of molecular biomarkers for diagnosing localized prostate cancer (PCa), from the prostate-specific antigen (PSA) test to newer blood, urine, or tissue-based
APA
Shee K, Cooperberg MR (2026). Molecular Biomarkers for Localized Prostate Cancer: Current Progress and Future Directions.. The Urologic clinics of North America, 53(1), 15-32. https://doi.org/10.1016/j.ucl.2025.09.006
MLA
Shee K, et al.. "Molecular Biomarkers for Localized Prostate Cancer: Current Progress and Future Directions.." The Urologic clinics of North America, vol. 53, no. 1, 2026, pp. 15-32.
PMID
41265996 ↗
Abstract 한글 요약
This article examines the current landscape of molecular biomarkers for diagnosing localized prostate cancer (PCa), from the prostate-specific antigen (PSA) test to newer blood, urine, or tissue-based biomarkers which can improve the accuracy of PCa diagnosis compared with PSA alone. The article further examines how tissue-based biomarkers are being used for predicting outcomes and affecting treatment decisions. These biomarkers have the potential to transform the clinical management of PCa, but future studies are needed to optimize and standardize their use in combination with other tests, including modern imaging, to provide maximum benefit to PCa patients.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (4)
- A High Decipher Genomic Risk Score Is Associated with Major Pathological Progression in Patients Undergoing Active Surveillance for Prostate Cancer.
- Gleason Grade Group 3 Represents a Spectrum of Disease: Results from a Large Institutional Cohort.
- The Natural History of Confirmed Grade Group 1 Prostate Cancer Managed with Active Surveillance in the Modern Era.
- Determining Optimal Patient Selection for High-intensity Focused Ultrasound for Prostate Cancer.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.
- Early local immune activation following intra-operative radiotherapy in human breast tissue.